Maven returns to direct to consumer platform

This pushes Maven beyond being a benefit chosen by HR and turns it into a healthcare brand that can acquire and keep patients on its own. The consumer product lets Maven sell directly to women who want fast access to virtual care, menopause support, or GLP-1 treatment, then keep them inside the same network for adjacent needs across 30+ specialties, using a 600+ provider base that was originally built for the employer business.1 2 3 4

• Maven started as a direct pay telehealth marketplace in 2015, then spent years building its larger employer and health plan business. Returning to consumer is less a new bet than a reuse of the same clinical supply, care navigation, and specialist network for a cash pay front door.1 5
• The product mix shows where consumer health demand is strongest. Virtual clinic visits widen the top of funnel, while GLP-1 care and hormone care are higher intent programs with clearer recurring spend, similar to how D2C telehealth players like Ro used one condition to acquire customers and then expanded into more services.2 3 6
• This also gives Maven a hedge against the limits of enterprise sales. Employer contracts are lumpy and controlled by benefits budgets, while consumer revenue comes from individual patients paying monthly or per visit. That matters for a company already estimated at $268M ARR and 98% customer retention in its core platform.5 7

The next step is a blended model where enterprise and consumer reinforce each other. Maven can use employer distribution to build trust, then convert uncovered or post employment demand into self pay care, especially in menopause and weight management, where ongoing treatment makes the relationship more durable and raises lifetime value.2 3 4 6